Our results showed a higher expression of these genes in SCLC patients compared to the healthy controls; of note, patients with low ERCC1 and ERCC5 expression had better mPFS and mOS, while an inverse trend emerged in survival outcomes for ERCC2 expression. This evidence concerns the gene ERCC2 and small cell lung carcinoma.